A Two-Color Haploid Genetic Screen Identifies Novel Host Factors Involved in HIV-1 Latency

• Published in: mBio Vol. 12; no. 6; p. e0298021
• Main Authors: Röling, Michael, Mollapour Sisakht, Mahsa, Ne, Enrico, Moulos, Panagiotis, Crespo, Raquel, Stoszko, Mateusz, De Crignis, Elisa, Bodmer, Helen, Kan, Tsung Wai, Akbarzadeh, Maryam, Harokopos, Vaggelis, Hatzis, Pantelis, Palstra, Robert-Jan, Mahmoudi, Tokameh
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 21-12-2021
• Subjects: CD4-Positive T-Lymphocytes - metabolism; CD4-Positive T-Lymphocytes - virology; DNA Helicases - genetics; DNA Helicases - metabolism; DNA-Binding Proteins - genetics; DNA-Binding Proteins - metabolism; Gene Expression Regulation, Viral; Genetics and Molecular Biology; haploid forward genetic screen; Haploidy; HIV Infections - genetics; HIV Infections - metabolism; HIV Infections - virology; HIV-1 - genetics; HIV-1 - physiology; host factor; Host-Pathogen Interactions; human immunodeficiency virus; Humans; latency; Receptors, Kainic Acid - genetics; Receptors, Kainic Acid - metabolism; Research Article; Trans-Activators - genetics; Trans-Activators - metabolism; Transcription Factors - genetics; Transcription Factors - metabolism; Ubiquitin-Specific Proteases - genetics; Ubiquitin-Specific Proteases - metabolism; Virus Activation; Virus Latency; human immunodeficiency virus; haploid forward genetic screen; host factor; latency
• ISSN: 2150-7511; 2150-7511
• DOI: 10.1128/mBio.02980-21

To identify novel host factors as putative targets to reverse HIV-1 latency, we performed an insertional mutagenesis genetic screen in a latent HIV-1 infected pseudohaploid KBM7 cell line (Hap-Lat). Following mutagenesis, insertions were mapped to the genome, and bioinformatic analysis resulted in the identification of 69 candidate host genes involved in maintaining HIV-1 latency. A select set of candidate genes was functionally validated using short hairpin RNA (shRNA)-mediated depletion in latent HIV-1 infected J-Lat A2 and 11.1 T cell lines. We confirmed ADK, CHD9, CMSS1, EVI2B, EXOSC8, FAM19A, GRIK5, IRF2BP2, NF1, and USP15 as novel host factors involved in the maintenance of HIV-1 latency. Chromatin immunoprecipitation assays indicated that CHD9, a chromodomain helicase DNA-binding protein, maintains HIV-1 latency via direct association with the HIV-1 5' long terminal repeat (LTR), and its depletion results in increased histone acetylation at the HIV-1 promoter, concomitant with HIV-1 latency reversal. FDA-approved inhibitors 5-iodotubercidin, trametinib, and topiramate, targeting ADK, NF1, and GRIK5, respectively, were characterized for their latency reversal potential. While 5-iodotubercidin exhibited significant cytotoxicity in both J-Lat and primary CD4
T cells, trametinib reversed latency in J-Lat cells but not in latent HIV-1 infected primary CD4
T cells. Importantly, topiramate reversed latency in cell line models, in latently infected primary CD4
T cells, and crucially in CD4
T cells from three people living with HIV-1 (PLWH) under suppressive antiretroviral therapy, without inducing T cell activation or significant toxicity. Thus, using an adaptation of a haploid forward genetic screen, we identified novel and druggable host factors contributing to HIV-1 latency.
A reservoir of latent HIV-1 infected cells persists in the presence of combination antiretroviral therapy (cART), representing a major obstacle for viral eradication. Reactivation of the latent HIV-1 provirus is part of curative strategies which aim to promote clearance of the infected cells. Using a two-color haploid screen, we identified 69 candidate genes as latency-maintaining host factors and functionally validated a subset of 10 of those in additional T-cell-based cell line models of HIV-1 latency. We further demonstrated that CHD9 is associated with HIV-1's promoter, the 5' LTR, while this association is lost upon reactivation. Additionally, we characterized the latency reversal potential of FDA compounds targeting ADK, NF1, and GRIK5 and identify the GRIK5 inhibitor topiramate as a viable latency reversal agent with clinical potential.